[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condbio:mantle-cell-lymphoma:ccnd1-gene":3},{"condition":4,"biomarker":5,"total":6,"trials":7},"Mantle Cell Lymphoma","CCND1 Gene",3,[8,16,23],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT05976763","Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma",[12],"Phase 3","RECRUITING","2026-08-26T02:17:07.954622Z","2026-07-19T19:36:05.124289Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT05861050","Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma",[20],"Phase 1\u002FPhase 2","2026-08-26T02:19:25.538428Z","2026-05-05T02:43:28.958425Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":27,"content_modified":28},"NCT06357676","Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma, IGNITE MCL Trial",[20],"2026-08-26T02:15:02.712396Z","2026-05-05T02:43:28.817702Z"]